Cytokine levels in malignant ascites and peripheral blood of patients with advanced ovarian cancer

被引：35
|
作者：
Radke, J
Schmidt, D
Bohme, M
Schmidt, U
Weise, W
Morenz, J
机构：
[1] OTTO VONGUERICKE UNIV,FAK MED,INST IMMUNOL,D-39008 MAGDEBURG,GERMANY
[2] OTTO VONGUERICKE UNIV,FAK MED,KLIN ST MARIENSTIFT MAGDEBURG,D-39008 MAGDEBURG,GERMANY
[3] OTTO VONGUERICKE UNIV,FAK MED,INST BIOMETRIE & MED INFORMAT,D-39008 MAGDEBURG,GERMANY
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 1996年 / 56卷 / 02期
关键词：
D O I：
10.1055/s-2007-1022247
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
The concentrations of various cytokines were examined by ELISA in blood and in ascites from 14 patients with advanced ovarian cancer (stage IV). The control group consisted of 6 patients with benign gynaecological disorders. Compared with patients with benign gynaecological disorders, ascites and/or plasma of patients with ovarian cancer showed significantly higher levels of IL-6, IL-8, IL-10, TNF-alpha, and sIL-2R. There were no increases of IL-1 alpha, IL-1 beta, IL-2, IFN-gamma, and sCD14 levels. The possible pathogenetic significance of cytokines in ovarian cancer is discussed.
引用
收藏
页码：83 / 87
页数：5
相关论文
共 50 条
  • [31] IMPORTANCE OF ASCITES IN OVARIAN CANCER PATIENTS
    Baert, T.
    D'heygere, V.
    Laenen, A.
    Vandecaveye, V.
    Timmerman, D.
    Vergote, I.
    Coosemans, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 629 - 629
  • [32] High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer
    Bojko, P
    Scheulen, ME
    Hilger, R
    Oberhoff, C
    Schindler, AD
    Seeber, S
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2001, 127 (04) : 243 - 250
  • [33] High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer
    Peter Bojko
    Max Ernst Scheulen
    Ralf Hilger
    Carsten Oberhoff
    Adolf Eduard Schindler
    Siegfried Seeber
    Journal of Cancer Research and Clinical Oncology, 2001, 127 : 243 - 250
  • [34] Tumor cell-fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer
    Han, Qing
    Huang, Bangxing
    Huang, Zaiju
    Cai, Jing
    Gong, Lanqing
    Zhang, Yifan
    Jiang, Jiahong
    Dong, Weihong
    Wang, Zehua
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2019, 44 (06) : 2245 - 2255
  • [35] Characterisation of the cell content of malignant ascites in advanced epithelial ovarian cancer and clinico-pathological correlations
    Wall, L
    Burke, F
    Smyth, J
    Balkwill, F
    BRITISH JOURNAL OF CANCER, 2002, 86 : S45 - S46
  • [36] Cytokine levels in supernatants of peripheral blood lymphocytes of patients with amyotrophic lateral sclerosis
    Bongioanni, P.
    De Tata, V.
    Metelli, M. R.
    Martino, L.
    Fulceri, F.
    Manzone, F.
    Rossi, B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 268 - 269
  • [37] Current and Future Options in the Treatment of Malignant Ascites in Ovarian Cancer
    Woopen, Hannah
    Sehouli, Jalid
    ANTICANCER RESEARCH, 2009, 29 (08) : 3353 - 3359
  • [38] Malignant ascites determine the transmesothelial invasion of ovarian cancer cells
    Mikula-Pietrasik, Justyna
    Uruski, Pawel
    Szubert, Sebastian
    Szpurek, Dariusz
    Sajdak, Stefan
    Tykarski, Andrzej
    Ksiazek, Krzysztof
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2017, 92 : 6 - 13
  • [39] Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer
    Hamilton, Chad A.
    Maxwell, G. Larry
    Chemofsky, Mildred R.
    Bernstein, Sarah A.
    Farley, John H.
    Rose, G. Scott
    GYNECOLOGIC ONCOLOGY, 2008, 111 (03) : 530 - 532
  • [40] Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: Preliminary results of a pilot study
    Colombo, N.
    Mangili, G.
    Mammoliti, S.
    Kalling, M.
    Tholander, B.
    Sternas, L.
    Buzenet, G.
    Chamberlain, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345